Search the Newsreel

Is MannKind (MNKD) Undervalued After Positive INFLO 1 Data For Its IPF Pipeline?

MannKind (MNKD) has seen increased investor interest following positive Phase 1b INFLO-1 data for its inhaled nintedanib therapy, leading to a recent stock price jump. Despite short-term momentum, the stock remains down year-to-date and over a three-year period. A widely followed narrative suggests MannKind …

Mannkind director Steven Binder sells $158,547 in common stock By Investing.com

Mannkind director Steven B. Binder sold 39,051 shares of the company's common stock for a total of $158,547 on August 7, 2026, as part of a Rule 10B5-1 trading plan. Despite a recent loss per share, analysts predict positive earnings for fiscal 2026 with …

MannKind Corp (MNKD) Director Steven Binder Sells 39,051 Shares

MannKind Corp Director Steven Binder sold 39,051 shares of MNKD on August 7, 2026, for approximately $158,547, increasing his total sales over the past year to 108,476 shares. This insider selling trend, with 12 sells against 1 buy, contrasts with institutional activity where 4 …

Why MannKind (MNKD) Is Up 5.1% After Positive Inhaled Nintedanib Data Despite Q2 Net Loss

MannKind (NASDAQ:MNKD) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded MannKind (NASDAQ:MNKD) from "hold" to "sell," despite a broader analyst consensus of "Moderate Buy" with an average price target of $9.22. The biopharmaceutical company's shares opened at $4.11, up 5.7%, but reported a Q1 loss of $0.05 per share and …

MannKind (MNKD) insider Steven Binder plans 39,051-share Rule 144 stock sale

MannKind Corporation insider Steven Binder plans to sell up to 39,051 common shares under Rule 144 through Morgan Stanley Smith Barney LLC. This filing also discloses previous 10b5-1 plan sales by Binder, including 52,485 shares on July 17, 2026, and 16,940 shares on May …

MannKind (MNKD) Stock Faces Margin Strain Despite Stronger Product Sales

MannKind Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:MNKD) 2026-08-06

MannKind Corp Q2 2026: Revenue $109.4M, EPS $(0.06) — 10-Q Summary

MannKind Corp reported its second-quarter 2026 results, showing a significant increase in revenue to $109.4M, up from $76.5M in the prior year, primarily due to the acquisition of scPharma and the addition of Furoscix. Despite revenue growth, the company recorded a net loss of …

MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says

Wedbush analysts anticipate higher revenue for MannKind in the second half of the year due to its increasingly diversified portfolio. The company's focus for 2026 is on commercial and clinical execution, with Furoscix therapy being a key priority.

MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts ...

This article first appeared on GuruFocus. Second Quarter Revenue: $109.4 million, up 43% year-over-year. First Half Revenue: $199.5 million, up 29% over the first half of 2025. Afrezza Net Sales: $17 million in Q2 2026. Furosix Net Sales: $22.2 million, up 43% from Q1 …

MannKind (NASDAQ:MNKD) Announces Quarterly Earnings Results

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, MannKind (MNKD) reported revenue of $109.37 million, up 42.9% over the same period last year. EPS came in at -$0.06, compared to $0 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $106.95 …

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MannKind Corporation reported strong Q2 2026 financial results with total revenues of $109.4 million, a 43% increase year-over-year. The company highlighted three major catalysts for future growth: the launch of Afrezza's pediatric indication, FDA approval of the Furoscix ReadyFlow™ autoinjector, and positive Phase 1b …

Earnings Flash (MNKD) MannKind Corporation Posts Q2 Adjusted Loss $0.01 per Share

MannKind earnings in focus after FUROSCIX ReadyFlow approval

MannKind Corp is set to release its second-quarter earnings, with analysts anticipating a loss of 1 cent per share on revenue of $109.02 million, reflecting a significant year-over-year increase. The biopharmaceutical company is expected to capitalize on the recent FDA approval of FUROSCIX ReadyFlow, …

MannKind Q2 2026 Earnings: Revenue Rises 43% as Costs Drive a Net Loss

MannKind Corporation reported a 43% increase in Q2 2026 revenue, reaching $109.4 million, primarily due to the acquisition of scPharma and increased collaboration income. However, the company experienced a net loss of $19.0 million, an adverse swing from a profit of $0.7 million in …

MannKind (NASDAQ: MNKD) posts $199M H1 2026 revenue after scPharma deal

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind (MNKD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children

MannKind Corporation's (MNKD) stock gained about 5% after the FDA approved its Afrezza Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes. This makes Afrezza the first and only needle-free, inhaled mealtime insulin available for pediatric …

MannKind Corp (MNKD) Financial Health: Profitability & Balance Sheet Analysis

MannKind Corp (MNKD) has a current financial score of 7.90, ranking 72 out of 384 in its industry, indicating weak financial status but high operating efficiency. The company recently reported a quarterly revenue of $90.17 million, marking a 15.08% year-over-year increase, and its net …

Vanguard Capital Management (MNKD) discloses 15.45M-share, 5% MannKind position

Vanguard Capital Management LLC and its affiliates have reported a passive 5% ownership stake in MannKind Corp (MNKD), holding 15,450,421 shares as of June 30, 2026. This disclosure was made via a Schedule 13G filing, indicating Vanguard's sole voting power over 2,281,029 shares and …

MannKind stock reiterated at Buy by H.C. Wainwright on trial data

H.C. Wainwright reiterated a Buy rating and a $10.00 price target for MannKind (NASDAQ:MNKD) after positive results from the INFLO-1 trial for its nintedanib dry powder inhaler. The trial showed good tolerability with no severe adverse effects, supporting the drug's development for idiopathic pulmonary …

MNKD|MannKind Corp|Price:4.115|Chg%:+0.265

This analysis of MannKind Corp (MNKD) by TradingKey highlights its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company shows significant institutional ownership and positive analyst ratings with a high …

MNKD: Phase I-B data show nintedanib DPI is safe and well-tolerated in IPF, enabling phase II advancement

MannKind Corporation (MNKD) announced positive Phase I-B results for its nintedanib Dry Powder Inhaler (DPI) in Idiopathic Pulmonary Fibrosis (IPF) patients. The study demonstrated strong safety and tolerability, with no serious adverse events and effective lung delivery, paving the way for a global Phase …

MannKind’s Inhaled Nintedanib Passes Safety Test in IPF Patients, Paving Way for Global Phase 2 Trial

MannKind's inhaled nintedanib therapy for Idiopathic Pulmonary Fibrosis (IPF) successfully cleared a Phase 1b safety study, demonstrating no serious adverse events or significant gastrointestinal side effects in 27 patients. This positive outcome, building on earlier healthy volunteer data, paves the way for a global …

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

MannKind Corporation (MNKD) will release its second quarter financial results on August 5, 2026, after the market closes. The company will also host a conference call and webcast at 5:00 PM ET on the same day to discuss the results and provide a business …

MNKD: Nintedanib DPI demonstrated strong safety and tolerability in IPF, supporting Phase 2 advancement

MannKind Corporation (MNKD) has announced Phase 1b results for nintedanib DPI, showing it to be safe and well-tolerated in Idiopathic Pulmonary Fibrosis (IPF) patients. The study reported no serious adverse events or discontinuations, with only mild, transient coughs. These positive results support the advancement …

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered in patients with IPFGlobal Phase 2 INFLO-2 trial actively enrolling patientsConference call and webcast scheduled for July …

MannKind Corp (MNKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of MannKind Corp (MNKD), detailing its price momentum score within the Biotechnology & Medical Research industry. It outlines the stock's current trading range between support and resistance levels, and analyzes various technical indicators like MACD, RSI, and Moving …

MannKind (MNKD) to Release Earnings on Wednesday

MannKind will review second-quarter results in Aug. 5 webcast

MannKind Corporation (Nasdaq: MNKD) announced it will report its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. The management team will host a conference call and live webcast at 4:30 p.m. Eastern Time to review the results and provide a …

H.C. Wainwright reiterates MannKind stock rating on FDA approval

H.C. Wainwright maintained a Buy rating and a $10.00 price target for MannKind (NASDAQ:MNKD) after the FDA approved FUROSCIX ReadyFlow, citing a potential upside of 142%. The firm expects ReadyFlow, an autoinjector for furosemide, to significantly boost revenue and margins starting in 2027, especially …